Primary Outcome Measures Number of participants treated with Alintegimod monotherapy with treatment related adverse events as assessed by CTCAEv5.0 Number of participants treated with Alintegimod in combination with treatment related adverse events as assessed by CTCAEv5.0 Define RPTDs for Alintegimod Secondary Outcome Measures Characterize Pharmacokinetics of Alintegimod monotherapy by measuring[…]
Pleural Mesothelioma
Targeting uPARAP Could Improve Mesothelioma Treatment
Mesothelioma is a hard cancer to treat that has low survival rates. This makes it a problem for doctors and researchers. A new study is looking to change this by looking at the collagen receptor uPARAP. The current clinical trial is looking at uPARAP, a protein that is found in[…]
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
3D Printing and Optical Scanning Can Improve Mesothelioma Treatment
New treatments and technologies offer hope for mesothelioma patients. One technology, 3D printing and optical scanning, has the potential to help those suffering with mesothelioma. The technologies refine and enhance what is known as photodynamic therapy, a promising new approach for the management of mesothelioma. Photodynamic therapy is a unique[…]
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)
Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD).
ADI-PEG20 Improves Survival in Mesothelioma Patients
ADI-PEG20 is showing promising results for mesothelioma. It is the first treatment to be fully incorporated with chemotherapy in 20 years. The drug will bring hope to thousands of mesothelioma survivors and their families. The drug works by blocking a cancer’s food supply, preventing the spread of the cancer. It[…]
Galinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients
Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the treatment called galinpepimut-S (GPS), an immunotherapy vaccine. There were 10 patients in the study with relapsed or refractory mesothelioma. Nine[…]
Breath Test Could Improve Diagnosis of Mesothelioma
A new way to diagnose mesothelioma may have been discovered. Researchers have found that the exhaled breath of patients could have the potential to be a screening tool for malignant pleural mesothelioma. The information was presented at the International Association for the Study of Lung Cancer 2023 World Conference on[…]
Altered CAR-T Cell Therapy for the Treatment of Mesothelioma
Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]
ADI-PEG 20 is Being Tested on Non-Epithelioid Mesothelioma
Polaris Group recently announced an application for a rolling submission of a new mesothelioma treatment. The Biologic License Application is the first step in becoming approved by the Food and Drug Administration. The treatment, known as ADI-PEG 20, is for the use on non-epithelioid mesothelioma patients alongside pemetrexed and platinum[…]
